Review

Molecular Process Producing Oncogene Fusion in Lung Cancer Cells by Illegitimate Repair of DNA Double-Strand Breaks

Yoshitaka Seki 1,2, Tatsuji Mizukami 1 and Takashi Kohno 1,*

1 Division of Genome Biology, National Cancer Center Research Institute, Chuo-ku, Tokyo 104-0045, Japan; E-Mails: yoseki@ncc.go.jp (Y.S.); tmizukam36@gmail.com (T.M.)

2 Division of Respiratory Diseases, Department of Internal Medicine, Jikei University School of Medicine, Minato-ku, Tokyo 105-8471, Japan

* Author to whom correspondence should be addressed: E-Mail: tkkohno@ncc.go.jp; Tel.: +81-3-3547-5272.

Academic Editors: Thomas Helleday, Wolf-Dietrich Heyer and Fumio Hanaoka

Received: 30 June 2015 / Accepted: 14 September 2015 / Published: 30 September 2015

Abstract: Constitutive activation of oncogenes by fusion to partner genes, caused by chromosome translocation and inversion, is a critical genetic event driving lung carcinogenesis. Fusions of the tyrosine kinase genes ALK (anaplastic lymphoma kinase), ROS1 (c-ros oncogene 1), or RET (rearranged during transfection) occur in 1%–5% of lung adenocarcinomas (LADCs) and their products constitute therapeutic targets for kinase inhibitory drugs. Interestingly, ALK, RET, and ROS1 fusions occur preferentially in LADCs of never- and light-smokers, suggesting that the molecular mechanisms that cause these rearrangements are smoking-independent. In this study, using previously reported next generation LADC genome sequencing data of the breakpoint junction structures of chromosome rearrangements that cause oncogenic fusions in human cancer cells, we employed the structures of breakpoint junctions of ALK, RET, and ROS1 fusions in 41 LADC cases as “traces” to deduce the molecular processes of chromosome rearrangements caused by DNA double-strand breaks (DSBs) and illegitimate joining. We found that gene fusion was produced by illegitimate repair of DSBs at unspecified sites in genomic regions of a few kb through DNA synthesis-dependent or -independent end-joining pathways, according to DSB type. This information will assist in the understanding of how oncogene fusions are generated and which etiological factors trigger them.
Keywords: lung cancer; oncogene; fusion; non-homologous end-joining; synthesis-dependent end-joining

1. Introduction

Fusion of ALK (anaplastic lymphoma kinase), ROS1 (c-ros oncogene 1), and RET (rearranged during transfection) oncogenes, which encode tyrosine kinases, with several partner genes by gross chromosome rearrangements is a genetic alteration that drives lung carcinogenesis by causing constitutive activation of these kinases. These gene fusions are mutually exclusive with each other and with mutations of other oncogenes, such as EGFR (epidermal growth factor receptor), KRAS (Kirsten rat sarcoma viral oncogene homolog), BRAF (B-Raf proto- oncogene), and ERBB2 (erb-b2 receptor tyrosine kinase 2), in lung adenocarcinoma (LADC) (Figure 1) [1–3]. Although ALK, ROS1, and RET fusions occur in a small subset (1%–5%) of LADCs, they are of particular interest for two reasons. First, drugs that inhibit ALK, ROS1, and RET kinases have marked therapeutic effects on fusion-positive LADCs because the survival and growth of such cancer cells are highly dependent on the kinase activity of fusion proteins. Second, ALK, ROS1, and RET fusions are preferentially detected in never- and light-smokers. Therefore, chromosome rearrangements producing oncogene fusions are likely to be smoking-independent, whereas activating mutations of the KRAS oncogene are strongly associated with tobacco smoking [4].

LADC is the most frequent histological type of lung cancer in Asian and European countries, and it is less associated with smoking than other types of lung cancers [5]. Therefore, elucidation of the mechanism(s) that causes oncogene fusions may help identify risk factors or preventive methods that could reduce the incidence of LADC. Chromosome rearrangements, such as translocation and inversion (Figure 2A), that produce oncogene fusions are supposedly caused by DNA double-strand breaks (DSBs) and subsequent illegitimate repair (i.e., joining) of broken DNA ends. Structural analysis of the breakpoints for such rearrangements is thought to be a powerful way to deduce the molecular processes underlying their occurrence because the breakpoints retain “traces” of DSBs and their subsequent repair [6,7]. This type of analysis provides information about the locations (clustering) of breakpoints on a genomic segment, which enables the identification of the genomic/chromosomal features that make DNA susceptible to DSBs, as well as the structures of breakpoint junctions, which enables the identification of the DSB repair pathways used for illegitimate joining of broken DNA ends. In this review, we summarize the information about breakpoint junctions of ALK, ROS1, and RET fusions obtained in our previous genomic analyses [3,8–12], and examined how oncogene fusions are generated in the course of carcinogenesis.
Figure 1. Mutually exclusive occurrence of oncogene aberrations in lung adenocarcinomas (LADC). Data on patients in Japan (A) and of European descent (B) were generated by summarizing the results of previous reports. Molecular target drugs for each oncogene aberrations are shown in blue (approved for lung cancer) or black (in clinical or preclinical studies). Anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), and rearranged during transfection (RET) oncogene fusions are present in a subset of LADCs in both populations.
Figure 2. Cluster of breakpoints in oncogenes and partner genes. (A) Chromosome inversion and translocation producing oncogene fusions. (B–D) Distribution of breakpoints in ALK and its major partner gene EML4 (B), ROS1 and its major partner gene CD74 (C), and RET and its major partner gene KIF5B (D). Yellow arrowheads indicate the locations of breakpoints for fusions in 41 Japanese LADC cases. All these cases were identified in a Japanese LADC cohort of 608 cases [8]. Breakpoints for chromosome rearrangements were identified by
next-generation sequencing and/or genomic PCR analyses of tumor DNAs as previously described [9]. Breakpoint cluster regions are gray-hatched for partner genes and orange-hatched for oncogenes. Breakpoints in tumors of smokers are marked by asterisks.

2. Distribution of Breakpoints in Oncogenes and Partner Genes

The location (clustering) of the breakpoints for chromosome rearrangements of ALK, ROS1, and RET fusions is illustrated in Figure 2B–D (detailed data in Supplementary Tables 1–2 and Supplementary Figure 1). As we reported for the RET fusion [9], breakpoints in the ALK and ROS1 oncogenes are also clustered within a defined region of a few kilobases (kb) in size. Breakpoints in partner genes were also mapped within a defined region of several kb in size. Interestingly, none of the breakpoints were mapped at the same position. The location of breakpoints does not necessarily coincide with the location of DNA breaks because broken DNA ends are often enzymatically resected before joining [13,14]. However, the high diversity in the location of breakpoints indicates that DSBs triggering oncogenic ALK, ROS1, and RET fusions in LADC preferentially occur in a few defined regions, but at non-specific sites within these regions. The breakpoint locations were not apparently affected by the smoking history of patients; therefore, DNA damage due to smoking is unlikely to be an important factor for DSB formation (Figure 1). The breakpoint cluster regions lack repetitive sequence clusters and have an average GC content. Furthermore, histone modifications in these regions in cultured non-cancerous lung epithelial cells (SAEC: Human Small Airway Epithelial Cells) indicate they have a closed chromatin structure (http://dbtss.hgc.jp).

3. Canonical Non-Homologous End-Joining (NHEJ), a Major DSB Repair Pathway for Illegitimate Joining of DNA Ends

The structures of breakpoint junctions were studied to deduce the DNA repair pathways involved in the joining of broken DNA ends. To precisely deduce the molecular process of joining, including DNA end resection and duplication, reciprocal gene fusion cases were chosen for this analysis, such as a case in which both oncogenic EML4-ALK and non-oncogenic ALK-EML4 fusion DNA was retained in tumor cells (Table 1). Consistent with the findings to date [15,16], only about one-third (15/41, 37%) of cases had reciprocal fusions, while the remaining 26 cases retained only oncogenic fusion DNAs. In the reciprocal cases, nucleotide deletions occurred frequently (11/15; 73%) in the oncogene and/or partner gene loci during the joining (Table 1).

The structures of the breakpoint junctions indicated the involvement of two DSB repair pathways in the illegitimate joining of broken DNA ends. One is NHEJ, which joins DNAs that have extremely low (a few bp) or no homology between DNA ends and often inserts a few nucleotides at the junctions [13,14]. Nine (60%) of the 15 cases showed this feature (a representative case is shown in Figure 3A). NHEJ has canonical and non-canonical forms; in the latter, called alternative end-joining (alt-EJ), DNA ends are joined using microhomology of a few nucleotides, leaving an overlap of a few nucleotides at breakpoint junctions [13]. In these nine cases, joining was judged to be achieved by canonical NHEJ because overlap of nucleotides of three or more bp was not detected (Table 2). In the 26 non-reciprocal cases, the detailed joining mechanisms could not be deduced due to a lack of sequence information from breakpoints in reciprocal counterparts; however, overlap of nucleotides of three or more bp was detected
in only three cases (12%) (Table 2, representative cases are shown in Figure 4A–C). In total, 32/35 cases (91%) showed NHEJ involvement without the need for DNA end microhomologies (Figure 4D). Thus, canonical NHEJ, but not alt-EJ, is a major DNA repair pathway for illegitimate DNA end-joining producing gene fusions. This is consistent with a recent study of chromosome translocations triggered by artificial DSBs, which reported that canonical NHEJ, but not alt-EJ, is responsible for chromosome translocations in human cells, although the opposite is true in murine cells [17]. Interestingly, translocation junctions in blood tumors, which are driven by oncogene fusion, often lack microhomology at breakpoint junctions [18–21]. Thus, canonical NHEJ is likely to be a common DNA repair pathway for the illegitimate DNA end-joining that produces gene fusions in a variety of tumors.

Table 1. Structure of breakpoint junctions for ALK, ROS1, and RET reciprocal fusions in lung adenocarcinoma.

| Onco-gene | Sample name | Partner gene | Nucleotide deletion | DNA segment duplication | Mode of DNA end joining | Smoking |
|-----------|-------------|--------------|---------------------|-------------------------|------------------------|---------|
| ALK       | L07K165_T   | EML4         | 4-bp                | 5-bp                    | NHEJ                   | No      |
|           | AD09-357T   | EML4         | 4-bp                | -                       | NHEJ                   | No      |
|           | L07K154_T   | EML4         | -                   | -                       | NHEJ                   | No      |
|           | AD09-055T   | EML4         | -                   | -                       | SDEJ                   | No      |
| ROS1      | 103T        | CD74         | -                   | 32-bp                   | SDEJ                   | No      |
|           | BR0020      | KIF5B        | -                   | -                       | NHEJ                   | No      |
|           | L07K201T    | KIF5B        | 490-bp              | 15-bp                   | NHEJ                   | Yes     |
|           | 349T        | KIF5B        | 14-bp               | 1-bp                    | NHEJ                   | Yes     |
|           | AD08-341T   | KIF5B        | 16-bp               | 1-bp                    | NHEJ                   | No      |
|           | RET-024     | CCDC6        | 41-bp               | 14-bp                   | SDEJ                   | No      |
| RET       | RET-030     | CCDC6        | 1021-bp             | 14-bp                   | NHEJ                   | No      |
|           | AD12-106T   | KIF5B        | -                   | 573-bp                 | SDEJ                   | Yes     |
|           | BR0030      | KIF5B        | 211-bp              | -                       | SDEJ                   | No      |
|           | 442T        | KIF5B        | 235-bp              | -                       | SDEJ                   | No      |
|           | AD08-144T   | KIF5B        | 2576-bp             | -                       | SDEJ                   | No      |

Table 2. Structure of breakpoint junctions for ALK, ROS1, and RET fusions determined to be caused by NHEJ.

| Onco-gene | Sample name | Partner gene | Reciprocal | Nucleotide overlap at junction | Nucleotide insertion at junction | Mode of NHEJ | Smoking |
|-----------|-------------|--------------|------------|-------------------------------|---------------------------------|--------------|---------|
| ALK       | L07K165_T   | EML4         | yes        | GG                            | -                               | C-NHEJ       | No      |
|           | AD09-357T   | EML4         | yes        | T                             | -                               | C-NHEJ       | No      |
|           | L07K154_T   | EML4         | yes        | -                             | AC                              | C-NHEJ       | No      |
|           | 43T         | EML4         | no         | T                             | -                               | C-NHEJ       | Yes     |
|           | 137T        | EML4         | no         | CT                            | -                               | C-NHEJ       | Yes     |
|           | 169T        | EML4         | no         | -                             | -                               | C-NHEJ       | Yes     |
|           | 236T        | EML4         | no         | TA                            | -                               | C-NHEJ       | No      |
|           | 255T        | EML4         | no         | AAC                           | -                               | Alt-EJ       | No      |
|           | L07K098_T   | EML4         | no         | A                             | -                               | C-NHEJ       | No      |
|           | AD08_351T   | EML4         | no         | -                             | -                               | C-NHEJ       | Yes     |
|           | AD08_355T   | EML4         | no         | AATC                          | -                               | Alt-EJ       | No      |
|           | AD09-218T   | EML4         | no         | -                             | -                               | C-NHEJ       | No      |
|           | AD09-352T   | EML4         | no         | -                             | -                               | C-NHEJ       | Yes     |
Table 2. Cont.

| Onco-gene | Sample name | Partner gene | Reciprocal | Nucleotide overlap at junction | Nucleotide insertion at junction | Mode of NHEJ | Smoking |
|-----------|-------------|--------------|------------|-------------------------------|-------------------------------|--------------|---------|
| 121T      | CD74        | no           | -          | ATATA                         | C-NEHEJ                       | No           |         |
| 199T      | CD74        | no           | -          | GG                            | C-NEHEJ                       | No           |         |
| L07K147_T | EZR         | no           | -          | -                             | C-NEHEJ                       | No           |         |
| AD08_009T | CD74        | no           | -          | -                             | C-NEHEJ                       | No           |         |
| AD08_034T | EZR         | no           | T          | -                             | C-NEHEJ                       | No           |         |
| AD09-230T | CD74        | no           | AT         | -                             | C-NEHEJ                       | No           |         |
| AD09-254T | CD74        | no           | AC         | -                             | C-NEHEJ                       | Yes          |         |
| AD09-466T | EZR         | no           | -          | T                             | C-NEHEJ                       | Yes          |         |
| L07K201T  | KIF5B       | yes          | C          | ATA                           | C-NEHEJ                       | No           |         |
| 349T      | KIF5B       | yes          | A          | -                             | C-NEHEJ                       | Yes          |         |
| AD08-341T | KIF5B       | yes          | -          | -                             | C-NEHEJ                       | No           |         |
| RET-024   | CCDC6       | yes          | -          | -                             | C-NEHEJ                       | Yes          |         |
| RET-030   | CCDC6       | yes          | -          | -                             | C-NEHEJ                       | No           |         |
| BR1001    | KIF5B       | no           | AGT        | -                             | C-NEHEJ                       | No           |         |
| BR1002    | KIF5B       | no           | A          | -                             | C-NEHEJ                       | No           |         |
| AD09-369T | KIF5B       | no           | CTC        | -                             | Alt-EJ                        | No           |         |
| AD12-001T | KIF5B       | no           | -          | -                             | C-NEHEJ                       | Yes          |         |

Figure 3. Cont.
Figure 3. Deduction of joining repair pathways based on the structure of breakpoint junctions. (A) A representative case in which reciprocal fusion was determined to be caused by non-homologous end joining (NHEJ). Overlapping and deleted nucleotides at breakpoint junctions are indicated; (B) A representative case in which reciprocal fusion occurred with duplication of a genomic segment (indicated by black rectangle); (C) Molecular processes causing gene fusions in LADC. Illegitimate DSB repair by synthesis-dependent end-joining (SDEJ) and NHEJ produces oncogene fusion. The pathway used might depend on the type of DSB, i.e., replication-associated or not; (D) Deduced process of reciprocal EML4-ALK fusion by SDEJ causing duplication of an ALK genome segment at breakpoint junctions, as in the case of AD09-055T (Figure 3B).
Figure 4. Deduction of non-homologous end joining (NHEJ) modes based on the structures of breakpoint junctions. (A and B) Representative cases in which reciprocal fusion was deduced to be caused by canonical NHEJ. Joining was performed without (A) and with (B) nucleotide insertions. (C) Representative cases in which reciprocal fusion was deduced to be caused by alt-EJ. Joining was deduced to involve microhomologies of three or four base pairs. C, NHEJ causing gene fusions in LADC. Canonical NHEJ is a major NHEJ mode used for DNA end-joining.
4. Synthesis-Dependent End-Joining (SDEJ), another DSB Repair Pathway for Illegitimate Joining of DNA Ends

The structures of breakpoint junctions in the other six (40%) reciprocal cases indicated that another DSB repair pathway is responsible for illegitimate joining of broken DNA ends (Table 1). In these cases, DNA segments of 33–490 bp from either the oncogene or partner gene locus were retained at both the partner-oncogene and oncogene-partner fusion breakpoints, resulting in duplication of these segments (Figure 3B). The duplication was observed in all the ALK, ROS1, and RET fusions, indicating a significant contribution of this repair pathway to chromosome rearrangements producing gene fusions. In fact, such duplication at breakpoint junctions was also observed in translocations in an experimental model using human cells [17].

The most likely pathway for joining that causes segmental duplication is SDEJ (Figure 3C), in which a broken DNA end, produced by replication-associated DSBs, initiates synthesis on the sister chromatid after strand invasion in a process called break-induced replication (BIR) [22,23]. Reversed branch migration of the Holliday junction formed following strand invasion can release the invaded strand, which contains extra DNA material from the sister chromatid and is fused to the broken DNA of a different chromosome locus by NHEJ (Figure 3D). Involvement of such a repair pathway has also been suggested to be involved in the formation of BRAF fusions in a few pediatric brain tumors based on the finding that the breakpoint junction retains duplicated segments [24]. Thus, SDEJ might be a common mechanism for chromosome rearrangements producing gene fusions.

The mode of joining was not apparently affected by the smoking history of patients; therefore, DNA damage due to smoking is unlikely to be an important factor for repair pathway selection (Table 1). However, SDEJ is triggered by replication-associated DSBs, while NHEJ repairs any kind of DSB. Therefore, it can be speculated that replication-associated DSBs cause gene fusion by SDEJ, while other DSBs, including those in non-replicating cells, cause gene fusion by canonical NHEJ (Figure 3C).

5. Molecular Process for Chromosome Rearrangements Producing Gene Fusion

The structure of breakpoint junctions for ALK, ROS1, and RET fusions in LADCs enabled us to deduce the molecular process underlying the chromosome rearrangements that produce gene fusions. First, DSBs occur in a few defined regions, but at non-specific sites within these regions. DSBs are generated both in replicating and non-replicating cells. Second, illegitimate repair of DNA ends by canonical NHEJ or SDEJ causes chromosome rearrangements that produce gene fusion, depending on the type of DSBs (Figure 3C).

The environmental and endogenous factors inducing DSBs that trigger rearrangements remain unknown. However, the contribution of both NHEJ and SDEJ to end joining indicates that a variety of DSBs, including those produced by replication stress, increase the risk of gene fusion. Interestingly, a recent study suggested that the breakpoint cluster regions in RET are easily broken during replication through that actions of DNA topoisomerase [25]. In addition, immunohistochemical studies of lung tumor specimens indicate that large amounts of DSBs are produced in pre-malignant lung epithelial cells through replication stress; these cells are thought to be negative for oncogene aberrations, and the DSBs are considered to cause genome instability [26]. ALK, ROS1, and RET fusions are believed to be the
“first hit” oncogene aberrations driving lung carcinogenesis [2, 8]; therefore, such DSBs might trigger the illegitimate DSB repair that results in chromosome rearrangements and cause malignant transformation of pre-malignant cells.

6. Conclusions

Cancer cells carry many different types of genetic aberrations, including mutations and gross chromosomal rearrangements, the latter of which include chromosomal deletions, insertions, inversions, and translocations. A small subset of these aberrations function as “drivers” of carcinogenesis, whereas the remaining variations are “passengers” that accumulate as a consequence of cancer cell genome instability. Recent genome-wide sequencing studies, such as the analysis of 140 cases of non-lymphoid malignancies, including 19 lung cancer cases, enabled the identification of many of the DNA repair pathways that contribute to the formation of gross chromosomal rearrangements as a whole [6]. However, only limited mechanistic information is available about the rearrangements that function as drivers for the development of solid tumors. Interestingly, some oncogenic fusions, such as ETS fusions in prostate cancer, are caused by closed chain events involving rearrangements of “non-oncogenic loci” [27]. Here, we provide information about the molecular processes that drive oncogenic fusions, based on a study of ALK, ROS1 and RET fusions in LADC. A comparative study of the present information with that obtained previously from other driver rearrangements, as well as from rearrangements at non-oncogenic loci, should help determine more precisely how triggering of DNA damage causes cancer cells to develop and identify the factors that cause driver gene aberrations.

Acknowledgments

We thank Thomas Helleday of the Karolinska Institutet for thoughtful discussions and suggestions on our data. We also thank Mamoru Kato, Hitoshi Ichikawa, Sachiyu Mitani, Yoko Shimada, and Ayaka Otsuka of the National Cancer Center Research Institute for data acquisition and Shun-ichi Watanabe and Koji Tsuta for surgical samples. This study was approved by the Institutional Review Board of the National Cancer Center. This work was supported by Grants-in-Aid from the Japan Agency for Medical Research and Development (AMED) for the Health and Labor Sciences Research Expenses for Commission (the Practical Research for Innovative Cancer Control: H26-practical-general-007) and a Grant-in-Aid from the Japanese Society for the Promotion of Science (JSPS) and Scientific Research (B). The NCC Biobank is also supported by Management Expenses Grants from the Government to the National Cancer Center. No other potential conflicts of interest were disclosed.

Author Contribution

Conception, design and financial support: Takashi Kohno.
Data analysis and interpretation: Tatsuji Mizukami and Yoshitaka Seki.
Manuscript writing: Yoshitaka Seki and Takashi Kohno.

Conflicts of Interests

The authors declare no conflict of interest.
References

1. Kohno, T.; Nakaoku, T.; Tsuta, K.; Tsuchihara, K.; Matsumoto, S.; Yoh, K.; Goto, K. Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. *Transl. Lung Cancer Res.* 2015, 4, 156–164.

2. Shaw, A.T.; Hsu, P.P.; Awad, M.M.; Engelman, J.A. Tyrosine kinase gene rearrangements in epithelial malignancies. *Nat. Rev. Cancer* 2013, 13, 772–787.

3. Kohno, T.; Ichikawa, H.; Totoki, Y.; Yasuda, K.; Hiramoto, M.; Nammo, T.; Sakamoto, H.; Tsuta, K.; Furuta, K. KIF5B-RET fusions in lung adenocarcinoma. *Nat. Med.* 2012, 18, 375–377.

4. Dogan, S.; Shen, R.; Ang, D.C.; Johnson, M.L.; D’Angelo, S.P.; Paik, P.K.; Brzostowski, E.B.; Riely, G.J.; Kris, M.G.; Zakowski, M.F. Molecular epidemiology of EGFR and KRAS mutations in 3026 lung adenocarcinomas: Higher susceptibility of women to smoking-related KRAS-mutant cancers. *Clin. Cancer Res.* 2012, 18, 6169–6177.

5. Couraud, S.; Zalcman, G.; Milleron, B.; Morin, F.; Souquet, P.J. Lung cancer in never smokers—A review. *Eur. J. Cancer* 2012, 48, 1299–1311.

6. Yang, L.; Luquette, L.J.; Gehlenborg, N.; Xi, R.; Haseley, P.S.; Hsieh, C.H.; Zhang, C.; Ren, X.; Protopopov, A.; Chin, L. Diverse mechanisms of somatic structural variations in human cancer genomes. *Cell* 2013, 153, 919–929.

7. Kohno, T.; Yokota, J. Molecular processes of chromosome 9p21 deletions causing inactivation of the p16 tumor suppressor gene in human cancer: Deduction from structural analysis of breakpoints for deletions. *DNA Repair (Amst)* 2006, 5, 1273–1281.

8. Saito, M.; Shimada, Y.; Shiraishi, K.; Sakamoto, H.; Tsuta, K.; Totsuka, H.; Chiku, S.; Ichikawa, H.; Kato, M.; Watamabe, S.; et al. Development of lung adenocarcinomas with exclusive dependence on oncogene fusions. *Cancer Res.* 2015, 75, 2264–2271.

9. Mizukami, T.; Shiraishi, K.; Shimada, Y.; Ogiwara, H.; Tsuta, K.; Ichikawa, H.; Sakamoto, H.; Kato, M.; Shibata, T.; Nakano, T.; et al. Molecular mechanisms underlying oncogenic RET fusion in lung adenocarcinoma. *J. Thorac. Oncol.* 2014, 9, 622–630.

10. Tsuta, K.; Kohno, T.; Yoshida, A.; Shimada, Y.; Asamura, H.; Furuta, K.; Kushima, R. RET-rearranged non-small-cell lung carcinoma: A clinicopathological and molecular analysis. *Br. J. Cancer* 2014, 110, 1571–1578.

11. Yoshida, A.; Kohno, T.; Tsuta, K.; Wakai, S.; Arai, Y.; Shimada, Y.; Asamura, H.; Furuta, K.; Shibata, T.; Tsuda, H. ROS1-rearranged lung cancer: A clinicopathologic and molecular study of 15 surgical cases. *Am. J. Surg. Pathol.* 2013, 37, 554–562.

12. Yoshida, A.; Tsuta, K.; Nakamura, H.; Kohno, T.; Takahashi, F.; Asamura, H.; Sekine, I.; Fukayama, M.; Shibata, T.; Furuta, K.; et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. *Am. J. Surg. Pathol.* 2011, 35, 1226–1234.

13. Bunting, S.F.; Nussenzweig, A. End-joining, translocations and cancer. *Nat. Rev. Cancer* 2013, 13, 443–454.

14. Lieber, M.R. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. *Annu. Rev. Biochem.* 2010, 79, 181–211.

15. Dai, Z.; Kelly, J.C.; Meloni-Ehrig, A.; Slovak, M.L.; Boles, D.; Christacos, N.C.; Bryke, C.R.; Schonberg, S.A.; Otani-Rosa, J.; Pan, Q.; et al. Incidence and patterns of ALK FISH abnormalities seen in a large unselected series of lung carcinomas. *Mol. Cytogenet.* 2012, 5, doi:10.1186/1755-8166-5-44.
16. Yoshida, A.; Tsuta, K.; Nitta, H.; Hatanaka, Y.; Asamura, H.; Sekine, I.; Grogan, T.M.; Fukayama, M.; Shibata, T.; Furuta, K.; et al. Bright-field dual-color chromogenic in situ hybridization for diagnosing echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinomas. *J. Thorac. Oncol.* 2011, 6, 1677–1686.

17. Ghezraoui, H.; Piganeau, M.; Renouf, B.; Renaud, J.B.; Sallmyr, A.; Ruis, B.; Oh, S.; Tomkinson, A.E.; Hendrickson, E.A.; Giovannangeli, C.; et al. Chromosomal translocations in human cells are generated by canonical nonhomologous end-joining. *Mol. Cell* 2014, 55, 829–842.

18. Gillert, E.; Leis, T.; Repp, R.; Reichel, M.; Hosch, A.; Breitenlohner, I.; Angermüller, S.; Borkhardt, A.; Harbott, J.; Lampert, F.; et al. A DNA damage repair mechanism is involved in the origin of chromosomal translocations t(4;11) in primary leukemic cells. *Oncogene* 1999, 18, 4663–4671.

19. Langer, T.; Metzler, M.; Reinhardt, D.; Viehmann, S.; Borkhardt, A.; Stanulla, M.; Creutzig, U.; Ritter, J.; et al. Analysis of t(9;11) chromosomal breakpoint sequences in childhood acute leukemia: Almost identical MLL breakpoints in therapy-related AML after treatment without etoposides. *Genes Chromosom. Cancer* 2003, 36, 393–401.

20. Zucman-Rossi, J.; Legoix, P.; Victor, J.M.; Lopez, B.; Thomas, G. Chromosome translocation based on illegitimate recombination in human tumors. *Proc. Natl. Acad. Sci. USA* 1998, 95, 11786–11791.

21. Mattarucchi, E.; Guerini, V.; Rambaldi, A.; Campiotti, L.; Venco, A.; Pasquali, F.; Lo Curto, F.; Porta, G. Microhomologies and interspersed repeat elements at genomic breakpoints in chronic myeloid leukemia. *Genes Chromosom. Cancer* 2008, 47, 625–632.

22. Hellday, T. Pathways for mitotic homologous recombination in mammalian cells. *Mutat. Res.* 2003, 532, 103–115.

23. Hellday, T.; Eshtad, S.; Nik-Zainal, S. Mechanisms underlying mutational signatures in human cancers. *Nat. Rev. Genet* 2014, 15, 585–598.

24. Lawson, A.R.; Hindley, G.F.; Forshew, T.; Tatevossian, R.G.; Jamie, G.A.; Kelly, G.P.; Neale, G.A.; Ma, J.; Jones, T.A.; Ellison, D.W.; et al. RAF gene fusion breakpoints in pediatric brain tumors are characterized by significant enrichment of sequence microhomology. *Genome Res.* 2011, 21, 505–514.

25. Dillon, L.W.; Pierce, L.C.; Lehman, C.E.; Nikiforov, Y.E.; Wang, Y.H. DNA Topoisomerases Participate in Fragility of the Oncogene RET. *PLoS ONE* 2013, 8, e75741.

26. Gorgoulis, V.G.; Vassiliou, L.V.; Karakaidos, P.; Zacharatos, P.; Kotsinas, A.; Liloglou, T.; Venere, M.; Ditullio, R.A., J.r.; Kastrinakis, N.G.; Levy, B.; et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. *Nature* 2005, 434, 907–913.

27. Berger, M.F.; Lawrence, M.S.; Demichelis, F.; Drier, Y.; Cibulskis, K.; Sivachenko, A.Y.; Sboner, A.; Esgueva, R.; Pflueger, D.; Sougnez, C.; et al. The genomic complexity of primary human prostate cancer. *Nature* 2011, 470, 214–220.

© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).